Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson JNJ, -0.19% said Thursday that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies.

Johnson & Johnson starts trial of COVID-19 vaccine after producing immune response in primates

NEW BRUNSWICK, N.J., July 30, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies.

Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies

Align Technology

3D Systems

SmileDirectClub

Dental stocks offer some risk, but some members of this industry have exciting growth prospects, particularly when Covid-19 is erased.

5 Dental Stocks to Buy For Big Smiles As Coronavirus Fears Ease

AstraZeneca

BioNTech SE

Catalent

Emergent BioSolutions

Lonza Group AG

Moderna

Novavax

Pfizer

The Race To Erase COVID-19

Abbott Labs

Baxter

Boston Scientific

Edwards Lifesciences

Globus Medical

Medtronic

NuVasive

Stryker

Health care is supposed to be a very defensive sector in investing. After all, diseases and conditions such as cancer, diabetes, heart disease, kidney failure, dementia, joint damage and spinal issues are just a small percentage of the ailments that have to be routinely treated.

Beyond COVID-19, Credit Suisse Shows Its Top Health Care Recovery Stock Picks

Sanofi

European efforts to secure potential COVID-19 vaccines from Pfizer , Sanofi and Johnson & Johnson are mired in wrangles over price, payment method and potential liability costs, three EU officials told Reuters.

Exclusive: EU talks with Pfizer, Sanofi, J&J on COVID vaccines hit snags - sources

There's a pretty good argument that it is.

Is Johnson & Johnson an Underdog in the COVID-19 Vaccine Race?

The good doctor is somewhat less optimistic than the leading coronavirus vaccine developers about timing.

Fauci: Coronavirus Vaccine Likely Not "Widely Available" Until Several Months Into 2021

Johnson & Johnson’s stock lost more than 23% – dropping from $146 at the beginning of the year to below $112 in late March – then spiked 35% to around $150 now. That means it has fully recovered to the levels where it started the year.

15% Upside For Johnson & Johnson Stock?

CNBC's Jim Cramer said Thursday that Johnson & Johnson has the most promising stock of the companies that are developing a vaccine to prevent Covid-19.

Cramer: Johnson & Johnson's stock stands out in the crowded race for a coronavirus vaccine

Coca-Cola

Altria

Realty Income Corp

The Federal Reserve has given another clear signal that there is less risk for investors, especially in long term.

Retirement Strategy: Blue Skies For Dividend Growth Investors, More Storms Ahead For Savers

General Dynamics

AT&T

Exxon Mobil

If you are a bond and income investor now, times are grim. The benchmark 10-year U.S.

Stock Dividend Yields the Highest Versus Bonds Since 1955: 5 to Buy Now for Income

The health care giant has been struggling with fines related to its role in the opioid crisis and talcum powder cancer charges.

Johnson & Johnson Below Risky Levels After Earnings Beat

Vaxart

The U.S. government is pouring money into coronavirus vaccine development, and a handful of companies are cashing in.

Everything You Need to Know About Operation Warp Speed's Coronavirus Vaccine Accelerator

Merck

Drug company executives insisted Tuesday they aren’t cutting corners in fast-tracking development of potential vaccines to prevent infection of the coronavirus.

Pharma executives promise Congress they aren't cutting corners in fast tracking coronavirus vaccine

The company is keeping its payout steady, despite declines in headline fundamentals in its Q2.

Dividend Aristocrat Johnson & Johnson Declares Fresh Dividend; Yield Is 2.7%

NEW BRUNSWICK, N.J., July 20, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2020 of $1.01 per share on the company's common stock.

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2020

Johnson & Johnson: A Core Dividend Growth Stock With Risks

JNJ is a Dow Jones Industrial Average component that makes consumer packaged goods, medical devices, and pharmaceuticals.

Johnson & Johnson: This Dividend Aristocrat Is Ready To Break Out

Colgate-Palmolive

The coronavirus pandemic didn't stop these giants from giving dividend investors what they want.

These 3 Dividend Aristocrats Have Already Boosted Their Payouts in 2020

The European Union is negotiating advance purchase deals of potential COVID-19 vaccines with drugmakers Moderna , Sanofi and Johnson & Johnson as well as biotech firms BioNtech and CureVac, two EU sources told Reuters.

Exclusive: EU in talks with Moderna, BioNtech, CureVac to secure possible COVID vaccines

Investors typically look at J&J's (JNJ) results for signals about how the rest of the big drugmakers will fare.

J&J Sets in Motion Pharma Q2 Earnings: 3 Stocks to Buy

Mastercard

Microsoft

When investing for the long-term, investors should prize stocks with strong management, wide moats and plenty of growth levers.

3 Best Long-Term Stocks to Set and Forget

Johnson & Johnson (NYSE: JNJ) said Thursday it would begin late-stage human trials for its COVID-19 vaccine ahead of schedule in September, with the phase one trials involving 1,000 people set to begin next week.

Johnson & Johnson Says Late-Stage Coronavirus Vaccine Trials Moved Ahead To September

Johnson & Johnson (JNJ) CEO Alex Gorsky on Q2 2020 Results - Earnings Call Transcript

News for Johnson & Johnson Stock (JNJ)